EnBiotix, Inc. announced that it has received $11 million in a round of funding on December 29, 2021. The transaction included participation from Vectura Group plc, Cystic Fibrosis Foundation, and returning investor Sanford Biosciences LLC. The company issued convertible note in the transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.031 CHF | +0.65% |
|
-25.12% | -24.39% |
06-12 | Spexis Resumes Trading on the SIX Swiss Exchange | MT |
06-05 | Spexis Appeals Suspension of Trading on SIX Swiss Exchange | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.39% | 2.35M | |
+2.22% | 93.53B | |
-1.71% | 38.27B | |
-12.83% | 32.84B | |
-12.14% | 16.08B | |
-0.68% | 14.02B | |
-12.63% | 11.47B | |
+163.45% | 9.92B | |
-53.23% | 9.42B | |
+3.52% | 8.98B |
- Stock Market
- Equities
- POLN Stock
- News Spexis AG
- EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation